Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Read more

Chairs and Members

ChairGiancarlo Castaman, University of Florence - Careggi University Hospital, Florence (Italy)

Co-chairAnna Falanga, University of Milan Bicocca and Hospital Papa Giovanni XXIII, Bergamo (Italy)

SWG Steering Committee
Ajay K Kakkar, Thrombosis Research Institute, London (United Kingdom)
Augusto Federici, University of Milan, University Hospital Luigi…

Read more

Chairs and Members

Chair (2017-present)Oliver A. Cornely—University Hospital Cologne, Cologne (Germany)

Co-chair (2023-present)Livio Pagano—Fondazione Policlinico A.

Read more

Chairs and Members

ChairJane Apperley

Co-chairAndreas Hochhaus

Executive Board members (2021–2027 term)
Prof Nicholas CP Cross, University of Southampton (UK)
Prof Oliver Hantschel, University of Marburg (Germany)
Dr Delphine Rea, University of Paris (France)
Dr Katerina Machova Polakova, Institute of Hematology and Blood Transfusion, Prague; Charles University (Czech Republic)
Prof…

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more

Chairs and Members

Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)

Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)

SWG Executive Board members and terms:

Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…

Read more

Chairs and Members

Chair:

Prof Arnon Kater (2021-2024)
Amsterdam University Medical Centers, University of Amsterdam
The Netherlands

Co-chair:

Prof Dr Sarka Pospisilova (2021-2024)
Masaryk Univerzity and Univerzity Hospital Brno
Czech Republic

SWG Executive Board members:

Carol Moreno (Hospital Sant Pau, Barcelona, Spain)

Richard Rosenquist (Karolinska Institute, Stockholm, Sweden)

Andy Rawstron (HMDS, Leeds, UK)

Yair Herishanu…

Read more

Writing and Publications WG

Responsibilities:
Authoring project and consensus papers.

Read more

Data Analysis and Interpretation WG

Responsibilities:
Managing and analyzing data centrally. Planning and implementing the necessary infrastructure and data transfer agreements.

Read more